The Future of Non–muscle-invasive Bladder Cancer: Towards a Molecular-Digital Paradigm for Personalized Management
European Urology Focus · 2026
DOI: 10.1016/j.euf.2026.01.005 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift European Urology Focus, 2026. Verfasst von Pierre-Etienne Gabriel und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Bichat Claude-Bernard Hospital, AP-HP, University Paris Cité, Paris, France. Hauptthemen laut MEDLINE: Non-Muscle Invasive Bladder Neoplasms, Precision Medicine, Urinary Bladder Neoplasms. Die Arbeit nennt 10 Literaturangaben.
Abstract (Originalsprache)
The management of non-muscle-invasive bladder cancer (NMIBC) is undergoing a major paradigm shift driven by molecular biomarkers, artificial intelligence (AI), and a better understanding of the tumor microenvironment and bladder microbiome. Traditional risk stratification based on stage and grade fails to capture the biological heterogeneity of NMIBC and its variable clinical behavior. Recent evidence highlights the prognostic and dynamic value of urinary and circulating tumor DNA for detecting aggressive disease, anticipating recurrence, and guiding treatment escalation. In parallel, AI-based models that integrate clinicopathological variables and computational histology significantly outperform current guideline-based risk calculators and thus allow refined patient stratification. Furthermore, emerging data demonstrate that immune infiltration patterns and microbiome composition influence response to intravesical therapies, particularly bacillus Calmette-Guérin. Together, these advances support a unified molecular-digital framework that integrates biomarkers, AI, and immunomicrobial profiling to personalize surveillance and treatment strategies. This evolving approach hold promise for optimizing bladder preservation and improving oncological outcomes in NMIBC. PATIENT SUMMARY: Combining tumor DNA tests, artificial intelligence tools, and analysis of the immune and microbial environment in the bladder may improve assessment of risk for patients with non-muscle-invasive bladder cancer. This approach could allow more personalized treatment and follow-up.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Bichat Claude-Bernard Hospital, AP-HP, University Paris Cité, Paris, France.
- Department of Urology, Bichat Claude-Bernard Hospital, AP-HP, University Paris Cité, Paris, France. Electronic address: evanguelos.xylinas@aphp.fr.
Zitieren
APA
Gabriel, P. E., & Xylinas, E. (2026). The Future of Non–muscle-invasive Bladder Cancer: Towards a Molecular-Digital Paradigm for Personalized Management. European Urology Focus. https://doi.org/10.1016/j.euf.2026.01.005
Vancouver
Gabriel PE, Xylinas E. The Future of Non–muscle-invasive Bladder Cancer: Towards a Molecular-Digital Paradigm for Personalized Management. European Urology Focus. 2026. doi:10.1016/j.euf.2026.01.005
BibTeX
@article{Gabriel2026,
author = {Gabriel, Pierre-Etienne and Xylinas, Evanguelos},
title = {The Future of Non–muscle-invasive Bladder Cancer: Towards a Molecular-Digital Paradigm for Personalized Management},
journal = {European Urology Focus},
year = {2026},
doi = {10.1016/j.euf.2026.01.005}
}
EUVIMED